P01 - The Effect of Feeding on the Pharmacokinetics of Telmisartan Oral Solution in Dogs

Abstract: Background - Telmisartan is an angiotensin receptor blocking drug that has great potential to improve the treatment of cardiovascular disease, renal disease, and hypertension in dogs. A telmisartan oral solution (TOS) is approved for use in cats, but the pharmacokinetics of this formulation have not been established in dogs. Previous studies have reported decreased bioavailability of telmisartan in cats and humans when administered with food, but whether the same is true for dogs is currently unknown.









Hypothesis/Objectives - To establish the pharmacokinetics of TOS and determine the effect of feeding on drug absorption in dogs.









Methods - Seven healthy dogs were included in this two-way, balanced, randomized, cross-over study. In two phases separated by a 7-day washout period, dogs were administered 1 mg/kg of TOS orally with or without food and underwent serial measurement of plasma telmisartan concentrations over 24 hours.









Results - No significant differences were found between the fasted and fed states in maximum concentration (253.46 ± 139.12 vs. 241.84 ± 121.85 ng/mL), time to maximum concentration (1.32 ± 0.66 vs. 1.46 ± 1.18 h), area under the curve (1376.06 ± 454.68 vs. 1239.05 ± 369.13 ng/mL), or terminal half-life (6.32 ± 2.13 vs. 5.35 ± 1.12 h).









Conclusions and clinical importance - These results indicate that TOS may be administered with or without food in dogs without a detrimental effect on bioavailability. However, additional pharmacokinetic and pharmacodynamic studies are warranted to confirm this recommendation and establish therapeutic targets to provide rational dosage recommendations for telmisartan in dogs.